First, there was a trend towards a higher expression of PD-L1 and MHC-I in lung cancer cell lines sensitive to erlotinib (EC50 <8) compared to those resistant to erlotinib (EC50 ≥8), but it was not statistically significant likely due to the heterogeneity of lung cancer cell lines and small number of lung cancer cell lines tested (Figs 2B and 4B). This evidence concerns the gene CD274 and lung cancer.